Research

Most of the research in the Division of Surgical Oncology is translational, in which ideas and hypotheses from the laboratory are incorporated into clinical evaluation through the clinical trial mechanism.

Active Research Grants

Carson WE. Core C: Clinical correlative science. National Cancer Institute P01, September 30, 2002 – August 31, 2006, $725,073.

Carson WE. Effect of IL-21 on antibody-dependent cellular cytotoxicity mediated by a Her2/neu antibody and NK cell against breast carcinoma cells in vitro and in vivo. ZymoGenetics, Inc., April 14, 2004 – July 31, 2006, $74,600.

Carson WE. Evaluation of immune activation following administration of interleukin-12 with an anti-HER2 antibody. Susan G. Komen Breast Cancer Foundation, May 1, 2003 – December 31, 2005, $29,978.

Carson WE. Modulation of tumor CEA levels for an anti-CEA vaccine. National Cancer Institute R21, May 18, 2005 – April 30, 2007, $583,587.

Carson WE. Multiparametric intracellular flow cytometry of immune cells for activated transcription factors in patients receiving interleukin-2 for metastatic malignant melanoma and renal cell carcinoma. Chiron Corp., April 1, 2005 – March 31, 2007, $39,995.

Carson WE. A phase 1 study of PA-341 (bortezomib, Velcade) and interferon-alpha-2b in malignant melanoma. Millennium Pharmaceuticals, Inc., February 10, 2005 – June 30, 2007, $107,000.

Carson WE. A program of immune-based treatments for cancer. National Cancer Institute K24, July 22, 2002 – June 30, 2007, $774,447.

Carson WE. Therapy of melanoma with bortexomib and interferon-alpha. National Cancer Institute R21, April 1, 2006 – February 28, 2007, $530,000.

Curley RW (Principal Investigator), Abou-Issa H. Analog studies of retinoid glucuronide activity. National Cancer Institute R01, April 1, 1999 – December 31, 2006, $2,967,700.

Farrar WB. Study of tamoxifen and raloxifene (STAR trial). National Surgical Adjuvant Breast and Bowel Project Foundation, June 1, 1999 – June 30, 2006, $636,485.

Farrar WB. Treatment of breast and bowel cancer patients: a clinical trial. National Surgical Adjuvant Breast and Bowel Project Foundation, February 1, 1999 – January 31, 2007, $404,695.

Kaumaya PTP (Principal Investigator), Carson WE, Shapiro CL, Fowler JM. Phase 1B active
immunotherapy with HER2 multi-epitope vaccine. National Cancer Institute R21, July 15, 2002 – June 20, 2006, $656,376.

Martin EW. Probe-assisted, PET/CT-guided surgery for colon cancer. National Institute for Biomedical Imaging R21, September 19, 2003 – August 31, 2006, $361,925.

Oberyszyn T (Principal Investigator), VanBuskirk A, Kusewitt DF. Therapeutic immunosuppressions, inflammation, and skin cancer. National Cancer Institute R01, April 1, 2005 – March 31, 2009, $1,141,944.

Povoski SP, Shapiro CL. A pilot trial of exemestane in combination with celecoxib as neoadjuvant treatment in postmenopausal women with stage II, III breast cancers. Pharmacia & Upjohn, June 27, 2003 – June 1, 2008, $119,000.

VanBuskirk A. Cytokine inhibition of CTL reactivation and post-transplant lymphoproliferative disorder (PTLD). Roche Organ Transplant, July 1, 2004 – August 31, 2005, $69,976.

VanBuskirk A. IFN-gamma and TGF-beta interactions in post-transplant lymphoproliferative disorder (PTLD). Roche Organ Transplantation Research Foundation, December 31, 2005 – December 30, 2006, $193,887.

VanBuskirk A. Immunomodulatory T cells in UV. American Cancer Society, Ohio Division,
September 1, 2004 – August 31, 2005, $30,000.

VanBuskirk A. The influence of clinically relevant immunosuppressants in an animal model to prevent post-transplant skin cancer (supplement to NIH grant). Roche Labs, Inc., March 10, 2005 – June 30, 2006, $2,700.

VanBuskirk A. Model for the prevention of post-transplant skin cancer. National Institutes of Health R03, July 9, 2004 – June 30, 2007, $149,500.

VanBuskirk A. The role of dysregulated inflammation post-transplant skin cancer. American Heart Association, Ohio Valley Affiliate, July 1, 2005 – June 30, 2007, $121,000.

VanBuskirk A, Ferketich A. Cytokine productions, gene polymorphisms, and PTLD. National Cancer Institute R03, September 22, 2004 – August 31, 2006, $149,500.

Walker MJ, Agnese D. A phase III multicenter randomized trial of sentinel lymphadenectomy and complete lymph node dissection versus sentinel lymphadenectomy alone in cutaneous melanoma with molecular or histopathological evidence of metastases in the sentinel node. John Wayne Cancer Institute (National Cancer Institute), May 1 – June 1, 2006, $42,800.

Walker MJ, Carson WE, Neki AS. BCG plus a polyvalent melanoma vaccine, CancerVax vaccine, plus BCG versus placebo, plus BCG as a postsurgical treatment for stage IV melanoma. CancerVax, February 1, 2002 – December 14, 2005, $18,953.

Walker MJ, Carson WE, Neki AS. BCG plus a polyvalent melanoma vaccine, CancerVax vaccine, versus BCG plus a placebo as a postsurgical treatment for stage III melanoma. CancerVax, February 1, 2002 – December 14, 2005, $161,177.

Yee LD. A dose-response study of omega 3 fatty acid supplements in women at high risk for breast cancer. University of Chicago, January 1 – May 31, 2006, $74,750.

Yee LD. Fatty acids and PPARs in breast cancer prevention. National Cancer Institute K07, September 1, 2000 – August 31, 2006, $663,250.

Yee LD. HER-2/neu and dietary fat: gene-nutrient interactions in breast cancer. National Cancer Institute R21, August 1, 2005 – July 31, 2007, $400,000.

Yee LD, Eng C. Rosiglitazone therapy in breast cancer. Department of Defense, September 15, 2001 – October 14, 2005, $440,857.